Genetic defects in ThTr1 (SLC19A2) and ThTr2 (SLC19A3) result in thiamine-responsive megaloblastic anemia (TRMA) and biotin-responsive basal ganglia disease (BBGD), respectively (2, 19, 20). Here, SLC19A3 is linked to biotin-responsive basal ganglia disease.